Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Global Vaccines Market 2008-2023
2.
Global Biotech Market Analysis and Forecasts, 2008-2023
3.
Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities
4.
Picture Archiving and Communications Systems (PACS)
5.
Microarray Markets
6.
Medical Nanotechnology Markets
7.
Contract Manufacturing Opportunities in High-Growth Medical Devices (Catheters, Pacemakers, LVADs, Hip and Knee Implants, Air Pathways, Syringes)
8.
Infusion Pump Markets (Large Volume, Ambulatory, Disposable, Syringe, and Specialty Infusion Pumps)
9.
Minimally Invasive Surgical Devices, World Market
10.
Innovative Strategies and Models for R&D Success: The evolving networked pharma company
Best Sellers:
1.
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, March 2008
2.
BioNewsCast Press Release Distribution Service
3.
Peripheral Neuropathy and Neuropathic Pain, 2008
4.
Blood Glucose Testing and Diabetes Management Report
5.
Autoimmune and Inflammation Rheumatoid Arthritis Drug Pipeline Report
6.
The Global Rheumatoid Arthritis Market Forecasts to 2012
7.
Biostatistics course
8.
Worldwide Surgical Sealants, Glues and Wound Closure Market, 2007-2011
9.
Good Manufacturing Practice (GMP) Course
10.
Good Clinical Practice I (GCP) course
Pricing and Reimbursement Series Medicare Part D's progress so far
Introduction
The roll-out of Part D in January 2006 represented a significant leap forward, since it provided coverage for outpatient drugs for Medicare patients for the first time. A high number of both patients and insurance providers are now involved in the program, as a result of strong patient enrollment.
Scope of this report
Overview of Part D enrollment, plus an analysis of how it has impacted the healthcare insurance market, and the branded and generic drug environment
Analysis of how Part D plans have changed from 2006 to 2007
Analysis of problems faced by Part D since its roll-out, and the identification of possible improvement areas going forward
Identification of how key issues such as the dual eligible patient population and drug sourcing in the donut hole are shaping Part D evolution
Research and analysis highlights
Uptake into Part D has been strong, and despite the size and complexity of the program, patient satisfaction has been relatively high. The program faced a number of teething problems during roll-out, which have largely been resolved (e.g. IT issues); however, there are still a number of issues that haven't been remedied.
A significant factor to impact Part D is the way that plan providers have handled patients covered by both Medicare and Medicaid. Providing these 'dual eligibles' with adequate coverage has been a significant challenge, particularly during the roll-out of the program.
The choice facing Part D beneficiaries about where to source drugs when they enter the gap in coverage in Part D programs (termed the donut hole) is also impacting plan providers and patients, since patient choice in this situation has a significant impact on market dynamics.
Key reasons to read this report
Gain a clear understanding of how Part D has evolved since its roll-out in January 2006
Understand the problems that Part D has faced, together with identifying areas for improvement
Gain insight into the key issues that are shaping Part D currently and in the future
Published: 30 March 2007
PDF Format
Table of Contents
Price: $3,800.00 / GBP1,976.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.